Description
Application
- For evaluation of drugs and screening of potential inhibitors to elastase proteases.
Key Features
- Safe. Non-radioactive assay.
- Homogeneous and convenient. Homogenous "mix-incubate-measure" type assay. No wash and reagent transfer steps are involved.
- Robust and high-throughput. Can be readily automated to assay thousands of samples per day. Robust assay with a Z' factor of > 0.8.
Method
- FL485/530nm
Samples
- Compounds that affect elastase enzyme activity.
Species
- All
Procedures
- 45 min
Size
- 100 tests (Custom bulk sizes available upon request)
Shelf Life
- 6 months
Screening Services
- BioAssay Systems offers comprehensive lead discovery services, including compound library screening, inhibitor profiling, and high-throughput assays to identify potential drug candidates. We provide detailed analyses of compound activity, potency, and selectivity, supporting hit-to-lead and lead optimization efforts. Please contact us.
More Details
PANCREATIC ELASTASE (PE, EC 3.4.21.36) and NEUTROPHIL ELASTASE (NE, EC 3.4.21.37) are serine proteases that exhibit similar elastin-degrading functions in different physiological roles. Neutrophil elastase is produced as an immune response to inflammation or infection, while pancreatic elastase hydrolyzes dietary proteins in many eukaryotic and prokaryotic organisms. BioAssay Systems' EnzyFluo™ Elastase Inhibitor Assay Kit uses a fluorescein isothiocyanate (FITC)-labeled synthetic substrate to quantify elastase activity in serine proteases. The fluorescein label is highly quenched. Upon digestion by elastase present in the sample, the substrate is cleaved into smaller peptides, which abolishes the quenching of the fluorescence label. The fluorescence or fluorescence polarization (FP) of the FITC-labeled fragments is measured at λex/em = 485/530 nm. Inhibition is determined by the decrease in fluorescence.
